The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.
 
Evan Rosenbaum
No Relationships to Disclose
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Hutchison MediPharma (Inst)
 
Ciara Marie Kelly
Research Funding - AGIOS (Inst); Amgen (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst)
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - AADi (Inst); Lilly (Inst)
 
Mary Louise Keohan
No Relationships to Disclose
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine; Rain Therapeutics
 
Katherine Anne Thornton
Consulting or Advisory Role - Adaptimmune; Agios; deloitte; Lilly; Macrogenics; More Health
Expert Testimony - Kilcoyne & Nesbitt
Travel, Accommodations, Expenses - adaptimmune
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; Exelixis; Merck (I)
Research Funding - Deciphera (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
 
Jason Earl Chan
Research Funding - Cytek Biosciences (Inst)
 
Benjamin Nacev
(OPTIONAL) Uncompensated Relationships - Delfi Diagnostics; QuadW Foundation; Rapafusyn Pharmaceuticals
 
Viswatej Avutu
No Relationships to Disclose
 
Matthew Biniakewitz
No Relationships to Disclose
 
Olivia Robin McKennan
No Relationships to Disclose
 
Haley Phelan
No Relationships to Disclose
 
Silvia Perez
No Relationships to Disclose
 
Sinchun Hwang
No Relationships to Disclose
 
Samuel Singer
No Relationships to Disclose
 
Li-Xuan Qin
Employment - MedImmune (I); Viela Bio (I)
Leadership - Viela Bio (I)
Stock and Other Ownership Interests - Viela Bio (I)
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - AbMaxBio; Adcendo; Agios; Ayala Pharmaceuticals; Blueprint Medicines; C4 Therapeutics; Daiichi Sankyo; Deciphera; EMD Serono; Kowa Pharmaceutical; Lilly; Mundipharma; NanoCarrier; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Sandra P. D'Angelo
Consulting or Advisory Role - Adaptimmune; Amgen; EMD Serono; GlaxoSmithKline; Immune design; Immunocore; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar